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Limb-girdle muscular dystrophy 1A (LGMD1A [MIM 159000]) is an autosomal dominant form of muscular
dystrophy characterized by adult onset of proximal weakness progressing to distal muscle weakness. We have
reported elsewhere a mutation in the myotilin gene in a large, North American family of German descent. Here,
we report the mutation screening of an additional 86 families with a variety of neuromuscular pathologies. We
have identified a new myotilin mutation in an Argentinian pedigree with LGMD1 that is predicted to result in the
conversion of serine 55 to phenylalanine (S55F). This mutation has not been found in 392 control chromosomes
and is located in the unique N-terminal domain of myotilin, only two residues from the T57I mutation reported
elsewhere. Both T57I and S55F are located outside the a-actinin and g-filamin binding sites within myotilin. The
identification of two independent pedigrees with the same disease, each bearing a different mutation in the same
gene, has long been the gold standard for establishing a causal relationship between defects in a gene and the
resultant disease. As a description of the second known pedigree with LGMD1A, this finding constitutes that gold
standard of proof that mutations in the myotilin gene cause LGMD1A.
The limb-girdle muscular dystrophies (LGMDs) include
a clinically diverse group of dominant and recessive dis-
orders characterized by proximal muscle weakness, el-
evated serum creatine kinase values, and absent or re-
duced deep-tendon reflexes. Among the autosomal
recessive limb girdles, mutations in calpain 3 cause
LGMD2A (Richard et al. 1995), mutations in dysferlin
cause LGMD2B (Bashir et al. 1998), and mutations in
telethonin cause LGMD2G (Moreira et al. 2000).
LGMD2C through LGMD2F are all caused by defects
in members of the dystrophin glycoprotein complex:
g-, a-, b-, and d-sarcoglycan (Roberds et al. 1994; Bon-
nemann et al. 1995; Lim et al. 1995; Noguchi et al.
1995; Nigro et al. 1996). Mutations in TRIM32, a pu-
tative E3-ubiquitin-ligase gene, have been identified as
the cause of LGMD2H (Frosk et al. 2002). Among the
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dominant forms, four have been mapped: LGMD1B to
1q11-21 (van der Kooi et al. 1997), LGMD1D to 6q23
(Messina et al. 1997), LGMD1E to 7q (Speer et al.
1999), and vocal cord and pharyngeal weakness with
autosomal dominant distal myopathy to 5q (Feit et al.
1998). Caveolin 3 mutations have been described in
LGMD1C (McNally et al. 1998; Minetti et al. 1998).
LGMD1A (MIM 159000) is characterized by onset
of proximal muscle weakness at a mean age of 27 years,
later progressing to include distal weakness. Approxi-
mately half of the affected individuals exhibit a distinc-
tive nasal, dysarthric pattern of speech. Tightened heel
cords and reduced knee and elbow deep-tendon reflexes
are frequently seen. CK levels are elevated, ranging from
1.6-fold to 9-fold higher than the normal limit of 120
IU/l for males and 80 IU/l for females. Biopsy of affected
individuals shows variations in fiber size, fiber splitting,
and other hallmarks of degeneration; a large number of
rimmed vacuoles; and patches of striking Z-line stream-
ing, similar to that seen in nemaline myopathy (Hauser
et al. 2000). Elsewhere, we have reported a mutation in
themyotilin gene (TTID,MYOT [NCBI accession num-
ber NM_006790; MIM 604103]) in the only known
LGMD1A pedigree, Duke family 39 (Hauser et al.
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Table 1
Primers Used to Amplify Myotilin Coding Sequence
EXON
PRIMER
PRODUCT SIZE
(bp)Forward Reverse
2a CAGATCTGAAAGATGTCAAATAAACAA GTTGTAACCCTTTGGCCTGG 546
2b CTCAACAAGGAAGAGCAGAC TACTGCTATTGTAATCAGGC 481
2c GCTCCAGATTGCAGCCTCCT CCAGTACCCTGGTTCAGCAT 476
3 ATTTGCAAAATGAGGCCAAG GGGCCCAAATATTCCTTCTT 373
4 TGTCTCAATAAATTCTCTAAAGCG GTGGATGGAACTGACCGACT 273
5 CTGGGCTTCTTGCTAGAGTGGTAG GATCCTGGCTTATTTGACC 462
6 CTCCTGCCTTAGCCTCCTGAG GGAGGATGGCAGAGCCAGAATT 471
7 TCTGCCATCTCCTTGTGTTTT TGAAGTCTGCTGGGCTTTTC 330
8 GGTATAACAAAATAGTACTGCATGTC AACTGGATTCACCCAAATAAAC 380
9 TGGTCAGAGACATCCACTTCA TTTTATACTCTGCTGGGATTTTCA 286
10a CCAATTTGGTTAGAACAGGTTT GTAGGCTTCACAAATCGGAG 420
10b TACCAACATTGGAAAACAG TCATAGGTTTTGCTGAGTGGAG 522
2000). Myotilin protein is localized to the Z-line and
binds to a-actinin (Salmikangas et al. 1999) and g-fi-
lamin (van der Ven et al. 2000b). The threonine 57 to
isoleucine (T57I) mutation in family 39 occurs in a re-
gion of unknown function, so the mechanism by which
it causes disease is not apparent.
We report here the screening of 86 additional pedi-
grees to find additional myotilin mutations that might
provide further insight into possible structure-function
relationships in the myotilin protein. LGMDs are char-
acterized by a large degree of variation in clinical pre-
sentation, between, and often within families. Individ-
uals with novel myotilin mutations may well present
with a significantly different set of symptoms from those
previously seen, especially if the mutations are located
in different protein domains. Therefore, mutation anal-
ysis was performed on at least one affected individual
from each of 44 families with LGMD type 1 (autosomal
dominant), 14 families with LGMD type 2 (autosomal
recessive), 24 families with facioscapulohumeral mus-
cular dystrophy, 2 families with scapuloperoneal mus-
cular dystrophy, and 2 families with unclassified domi-
nant myopathies. Informed consent was obtained from
all human subjects.
Mutation analysis was performed on genomic DNA
isolated from whole blood using the Puregene kit (Gen-
tra Systems). The primers in table 1 were used to PCR
amplify exons 2–9 and part of exon 10 (the full coding
region) of themyotilin gene from genomic DNA in pools
of five unrelated individuals. These PCR products were
analyzed using the Transgenomic WAVE denaturing
high-performance liquid chromatography system. Sev-
eral different temperatures were tested for each PCR
amplicon to optimize mutation detection sensitivity. All
observed changes were confirmed by sequencing both
DNA strands using the Beckman CEQ2000 capillary
electrophoresis sequencer or the Beckman 3700 DNA
sequencer using Big Dye chemistry.
A single Argentinian sample exhibited a C444rTmis-
sense mutation in exon 2 of the myotilin gene, predicted
to result in a change of residue 55 from serine to phe-
nylalanine (S55F). This change is found in a single allele,
consistent with the observed pattern of autosomal dom-
inant inheritance, and was not detected in 392 control
chromosomes. DNA samples from eight additional
members of this Argentinian pedigree (family 2654)
were then screened, and the missense mutation was
found to segregate with disease status. The FASST
method (Vance and Ben Othmane 1998) was used to
genotype family 2654 with two polymorphic microsat-
ellite repeat markers (D5S479 and D5S178) flanking the
myotilin gene (fig. 1). These markers establish a disease-
associated haplotype entirely different from that seen in
our original LGMD1A pedigree (Duke family 39).
The identification of two independent pedigrees with
the same disease, each bearing a different mutation in
the same gene, has long been the gold standard for es-
tablishing a causal relationship between defects in a gene
and the resultant disease. As a description of the second
known pedigree with LGMD1A, this finding constitutes
such gold-standard proof that mutations in themyotilin
gene cause LGMD1A. The clinical presentation of af-
fected individuals in family 2654 is quite similar to that
of the LGMD1A pedigree we reported elsewhere. They
exhibit proximal leg and arm weakness by 42–58 years
of age, which later progresses to include distal weakness.
Serum CK levels are elevated 5-fold to 15-fold. Two of
the four living affected individuals exhibit a distinctive
dysarthric pattern of speech. All members of family 2654
have been examined by two of the authors (A.L.R. and
G.Z.). The similarity in clinical presentation in the two
families may be related to the proximity of the observed
mutations, which are located 2 aa apart in the unique
N-terminal domain of the protein, immediately adjacent
to a 20-aa hydrophobic stretch.
There are striking similarities between LGMD1A and
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Figure 1 Segregation of 5q31 microsatellite markers and the C444T missense mutation in Family 2654. Affected individuals and the
disease-bearing haplotype are indicated in solid black. From top to bottom, the alleles shown are for D5S479, the S55F mutation, and D5S178.
the nemaline myopathies, suggesting possible mecha-
nisms by which myotilin mutations may give rise to dis-
ease. Missense mutations in a-tropomyosin (NEM1)
give rise to nemaline myopathy with Z-line streaming
similar to that seen in LGMD1A (Laing et al. 1995),
and both myotilin protein and a-tropomyosin bind to
a-actinin. One of the primary roles of a-actinin is to
tether actin filaments to the Z-line, and missense mu-
tations in a-actin also give rise to nemaline myopathy
(Nowak et al. 1999). These observations suggest that
the observedmyotilinmutations might act by disrupting
the tethering of actin filaments through their interactions
with a-actinin. However, we were unable to detect any
effect of the T57I mutation on a-actinin binding by
means of a yeast two-hybrid assay. Further, this assay
identified a minimum a-actinin binding domain extend-
ing from residues 79–150, well separated from the ob-
served mutations (Hauser et al. 2000).
It has also been reported that myotilin protein binds
to g-filamin, a form of filamin specifically expressed in
striated muscle, and does so through a region spanning
its 78-aa muscle-specific domain (van der Ven et al.
2000b). Several filamin isoforms bind to a-actin and are
thought to regulate its polymerization (Wang and Singer
1977). This network of actin filaments is then anchored
to the plasma membrane by filamin’s interactions with
a number of other cytoskeletal proteins, including b1-
integrin (Loo et al. 1998), b2-integrin (Sharma et al.
1995), and, in the case of g-filamin, g- and d-sarcoglycan
(Thompson et al. 2000). Further, g-filamin colocalizes
with a-actinin in the Z-disk in striated muscle and has
been implicated in Z-disk assembly and myofibrillo-
genesis (van der Ven et al. 2000a). Through its binding
interactions with both a-actinin and g-filamin, myotilin
protein may play a role in colocalizing a-actinin and g-
filamin to the Z-disk. This model is supported by the
observation that transfection of differentiating C2C12
myoblasts with a truncated myotilin gene encoding just
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the C-terminal Ig domains disrupts Z-disk formation,
whereas introduction of the entire myotilin gene does
not (van der Ven et al. 2000b). This would seem to
indicate that severing the connection between theN- and
C-terminal domains creates a dominant negative protein
in much the same way that the isolated Z1 and Z2 do-
mains of titin have been reported to disrupt sarcomere
assembly through their interactions with telethonin
(Peckham et al. 1997; Mues et al. 1998). It is unlikely
that the reported T57I and S55F myotilin mutations di-
rectly disrupt g-filamin binding: yeast two-hybrid ex-
periments have demonstrated that the g-filamin binding
site is located within the C-terminal Ig domains of my-
otilin protein (residues 215–493), well removed from the
T57I and S55F mutations (van der Ven et al. 2000b).
Although it is conceivable that the yeast two-hybrid sys-
tem is not sufficiently sensitive to detect the subtle effects
on tertiary structure caused by the myotilin mutations
and that these mutations actually do disrupt binding
with either a-actinin or g-filamin, a more likely expla-
nation is that there is another, as-yet-undeterminedbind-
ing partner for myotilin protein and that the observed
mutations disrupt this interaction or disrupt myotilin’s
ability to colocalize this protein with g-filamin.
The N-terminal region of myotilin protein that con-
tains the T57I and S55F mutations is not homologous
to any other protein. It includes a 23-residue hydropho-
bic domain and a region rich in serine (27/96 residues).
Although the function of this domain is unknown, it is
possible that the hydrophobic stretch mediates the lo-
calization of small amounts of myotilin protein to the
sarcolemmal membrane. Both of the observed myotilin
mutations would have the effect of elongating this hy-
drophobic stretch, possibly disturbing its interactions
with the sarcolemmal membrane or with a novel protein-
binding partner. A better understanding of the biological
function of the N-terminus will be necessary to fully
appreciate the effects of the two observed myotilin mu-
tations. Further, mutations in a different portion of the
protein might well result in a significantly different phe-
notype. For example, myotilin protein is expressed at
relatively high levels in the heart, and, although there is
no evidence of a cardiac defect in either known pedigree,
novel mutations might give rise to a cardiac phenotype.
We are currently testing this hypothesis by expressing
synthetic myotilin mutations in transgenic mouse mod-
els. These experiments may suggest alternate groups of
human patients who could be screened for defects in
myotilin.
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